Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, et al.
Cancer Letters (2019) Vol. 473, pp. 25-32
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Kyoko Oura, Asahiro Morishita, Joji Tani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5801-5801
Open Access | Times Cited: 313
Selecting Target Antigens for Cancer Vaccine Development
Luigi Buonaguro, Maria Tagliamonte
Vaccines (2020) Vol. 8, Iss. 4, pp. 615-615
Open Access | Times Cited: 104
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
Ramazan Rezaei, Hadi Esmaeili Gouvarchin Ghaleh, Mahdieh Farzanehpour, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 6, pp. 647-660
Open Access | Times Cited: 67
Immunotherapies for hepatocellular carcinoma
Justin K. H. Liu, Andrew F. Irvine, Rebecca Jones, et al.
Cancer Medicine (2021) Vol. 11, Iss. 3, pp. 571-591
Open Access | Times Cited: 63
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus Löffler, Stefania Gori, Francesco Izzo, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 12, pp. 2555-2566
Open Access | Times Cited: 51
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
Jiong-Jie Yu, Sunbin Ling, Jiachen Hong, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007479-e007479
Open Access | Times Cited: 23
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Yi Lu, Yue Gao, Huan Yang, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 36
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
Mingzhen Zhou, Sihui Zhu, Chen Xu, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 1, pp. 162-167
Open Access | Times Cited: 17
“Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma
Astha Malik, Unmesha Thanekar, Surya Amarachintha, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 36
Neoadjuvant Therapy for Hepatocellular Carcinoma
Zongyi Yin, Dongying Chen, Shuang Liang, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 929-946
Open Access | Times Cited: 25
CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer
Anil Kumar Mavi, Sonal Gaur, Gauri Gaur, et al.
Cellular Signalling (2023) Vol. 105, pp. 110638-110638
Closed Access | Times Cited: 15
Radiomics in the diagnosis and treatment of hepatocellular carcinoma
Chun Jiang, Yiqi Cai, Jiajia Yang, et al.
Hepatobiliary & pancreatic diseases international (2023) Vol. 22, Iss. 4, pp. 346-351
Closed Access | Times Cited: 14
Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment
Liwei Qiu, Yifei Liu, Xiaoqing Cao, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 18, pp. 2126-2137
Open Access | Times Cited: 35
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Cheng Zhong, Yirun Li, Jing Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 30
Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions
Xinguo Li, Xiaonan Sun, Bingyuan Wang, et al.
Asian Journal of Pharmaceutical Sciences (2022) Vol. 18, Iss. 1, pp. 100771-100771
Open Access | Times Cited: 21
Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma
Siyu Chen, Yiyang Sun, Yangla Xie, et al.
ACS Applied Materials & Interfaces (2024)
Closed Access | Times Cited: 3
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
Diederick J. van Doorn, R. Bart Takkenberg, Heinz‐Josef Klümpen
Pharmaceuticals (2020) Vol. 14, Iss. 1, pp. 3-3
Open Access | Times Cited: 26
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Ying Zhu, Lun‐Xiu Qin
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 420-429
Closed Access | Times Cited: 16
Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx
Lixing Li, Lu Shen, Jingsong Ma, et al.
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 19
p21-activated kinase 6 controls mitosis and hepatocellular carcinoma progression by regulating Eg5
Jiaojiao Zheng, Chunfeng Zhang, Yuan Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2020) Vol. 1868, Iss. 2, pp. 118888-118888
Closed Access | Times Cited: 17
HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p
Minyang Shi, Xuyang Lv, Mengqi Zhu, et al.
Anti-Cancer Drugs (2021) Vol. 33, Iss. 1, pp. e273-e285
Closed Access | Times Cited: 15
CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach
Xiaofei Zhang, Qin Hu, Xuesong He, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Novel Molecular Targets for Hepatocellular Carcinoma
Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 140-140
Open Access | Times Cited: 13
Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions
Xiao‐Wan Bo, Liping Sun, Song-Yuan Yu, et al.
World Journal of Gastrointestinal Oncology (2021) Vol. 13, Iss. 10, pp. 1397-1411
Open Access | Times Cited: 12
CircGNAO1 strengthens its host gene GNAO1 expression for suppression of hepatocarcinogenesis
Hongwei He, Qing Zhang, Qiyun Gu, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e32848-e32848
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top